Eloxx Pharmaceuticals, Inc. News Releases https://investors.eloxxpharma.com/ Eloxx Pharmaceuticals, Inc. News Releases en Eloxx Pharmaceuticals Reports First Quarter 2019 Financial and Operating Results and Provides Business Update https://investors.eloxxpharma.com/news-releases/news-release-details/eloxx-pharmaceuticals-reports-first-quarter-2019-financial-and Positive new preclinical data for Eloxx ERSG molecules presented at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting May 2, 2019 demonstrated: dose dependent restoration of missing protein of Usher Syndrome nonsense mutations, encouraging pharmacokinetics in the Thu, 09 May 2019 07:00:00 -0400 Eloxx Pharmaceuticals, Inc. News Releases 7086 Eloxx Pharmaceuticals Presents Positive New Data at the Association for Research in Vision and Ophthalmology “ARVO” 2019 Annual Meeting https://investors.eloxxpharma.com/news-releases/news-release-details/eloxx-pharmaceuticals-presents-positive-new-data-association Eloxx is evaluating several of its eukaryotic ribosomal selective glycoside (ERSG) molecules in IND-enabling studies for use in the treatment of inherited retinal diseases with an initial focus on Usher Syndrome Preclinical studies have demonstrated: dose-dependent restoration of missing protein of Thu, 02 May 2019 10:30:00 -0400 Eloxx Pharmaceuticals, Inc. News Releases 7081 Eloxx Pharmaceuticals to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019 https://investors.eloxxpharma.com/news-releases/news-release-details/eloxx-pharmaceuticals-report-first-quarter-2019-financial Company management to host a webcast and conference call to provide a business update and review financial results at 8:30 a.m. ET WALTHAM, Mass. , April 22, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery Mon, 22 Apr 2019 09:37:00 -0400 Eloxx Pharmaceuticals, Inc. News Releases 7066 Eloxx Pharmaceuticals to Participate in the 2019 5th Annual SunTrust Robinson Humphrey (STRH) Life Sciences Summit on May 7, 2019 https://investors.eloxxpharma.com/news-releases/news-release-details/eloxx-pharmaceuticals-participate-2019-5th-annual-suntrust WALTHAM, Mass. , April 15, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders and other diseases caused by Mon, 15 Apr 2019 13:15:00 -0400 Eloxx Pharmaceuticals, Inc. News Releases 7061 Eloxx Pharmaceuticals Presents Positive New Data for Lead Investigational Drug, ELX-02, at the European Cystic Fibrosis Society (ECFS) Basic Science Conference https://investors.eloxxpharma.com/news-releases/news-release-details/eloxx-pharmaceuticals-presents-positive-new-data-lead-1 ELX-02 shows significant increases in CFTR protein expression and localization correlating with functional activity in  Cystic Fibrosis patient-derived organoids bearing CFTR nonsense mutations In previous studies, the increased CFTR functional activity associated with ELX-02 was shown to correlate Wed, 27 Mar 2019 09:00:00 -0400 Eloxx Pharmaceuticals, Inc. News Releases 7036 Eloxx Pharmaceuticals to Present at the Guggenheim Rare Disease & Genomic Medicines Day on April 2, 2019 https://investors.eloxxpharma.com/news-releases/news-release-details/eloxx-pharmaceuticals-present-guggenheim-rare-disease-genomic WALTHAM, Mass. , March 20, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders, and other diseases caused by Wed, 20 Mar 2019 12:19:00 -0400 Eloxx Pharmaceuticals, Inc. News Releases 7026 Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial and Operating Results and Provides Business Update https://investors.eloxxpharma.com/news-releases/news-release-details/eloxx-pharmaceuticals-reports-fourth-quarter-and-full-year-2018 Eloxx announces the hiring of Dr. Susan Schneider as SVP Ophthalmology to lead the development of its rare inherited retinal disease programs Abstract accepted for presentation at European Cystic Fibrosis Society (ECFS) Basic Science Conference March 27-30, 2019 demonstrating ELX-02 activity in Fri, 08 Mar 2019 07:00:00 -0500 Eloxx Pharmaceuticals, Inc. News Releases 6996 Eloxx Pharmaceuticals to Present at the Oppenheimer 29th Annual Healthcare Conference on March 20, 2019 https://investors.eloxxpharma.com/news-releases/news-release-details/eloxx-pharmaceuticals-present-oppenheimer-29th-annual-healthcare WALTHAM, Mass. , March 05, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders, and other diseases caused by Tue, 05 Mar 2019 09:08:00 -0500 Eloxx Pharmaceuticals, Inc. News Releases 6986 Eloxx Pharmaceuticals Announces Participation in the HIT-CF Project on Cystic Fibrosis https://investors.eloxxpharma.com/news-releases/news-release-details/eloxx-pharmaceuticals-announces-participation-hit-cf-project Eloxx is evaluating ELX-02, its lead investigational compound, for the treatment of Cystic Fibrosis in patients with nonsense mutations WALTHAM, Mass. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. , (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the Tue, 26 Feb 2019 16:02:00 -0500 Eloxx Pharmaceuticals, Inc. News Releases 6976 Eloxx Pharmaceuticals to Present at the Barclays Global Healthcare Conference on March 14, 2019 https://investors.eloxxpharma.com/news-releases/news-release-details/eloxx-pharmaceuticals-present-barclays-global-healthcare WALTHAM, Mass. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders, and other diseases caused by Wed, 20 Feb 2019 16:00:00 -0500 Eloxx Pharmaceuticals, Inc. News Releases 6966